Pento-Gluc 200 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL
Published July 17, 2013 · Recall initiated: May 29, 2013
Summary
FDA records drug Class II recall D-767-2013, published July 17, 2013 and initiated May 29, 2013. Recalling firm: Lowlite Investments, Inc. D/B/A Olympia Pharmacy; Status: Ongoing; Reported quantity: 1; Lot: B0521 Exp 8/21/13. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Lowlite Investments, Inc. D/B/A Olympia Pharmacy
- Distributor
- Nationwide and PR
- Lot
- B0521 Exp 8/21/13
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAKetamine 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAMetabolase Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAAcetyl-D-Glucosamine w/Chondroitin 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDADiclazuril 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAPEN-DEX-CHLOR Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAPentosan 250 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
Questions about this recall
Was Pento-Gluc 200 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL recalled?
Yes. FDA published recall D-767-2013 on July 17, 2013. Reported hazard: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit